ScreenerHero

IMNM Immunome, Inc.

NAS · US · Healthcare · Biotechnology · immunome.com
19.09USD-1.11%Mkt Cap: 2.25B $P/E: —

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company d…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.25B USD
Enterprise Value1.68B USD
Revenue (TTM)0 USD
Gross Profit-206.23M USD
Net Income (TTM)-212.39M USD
Revenue/Share0.00 USD
Last Price19.09 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees247
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.96
PEG—
EV/EBITDA-6.51
EV/Revenue—
P/SInfinity
P/B4.17
EPS (TTM)-2.52
EPS (Forward)-2.43
52W Range
10.0045% of range30.06
52W High30.06 USD
52W Low10.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-3059.99%
ROE-33.48%
ROA-31.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-190.92M USD
CapEx (TTM)15.93M USD
FCF Margin—
FCF Yield-6.38%
Net Debt-515.26M USD
Net Debt/EBITDA2.00
Balance Sheet
Debt/Equity0.01
Current Ratio15.08
Quick Ratio14.64
Book Value/Sh4.63 USD
Cash/Share4.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.20 USD
Upside (mean)+84.3%
Target Range24.00 USD – 40.00 USD
24.00+84.3% to mean40.00
# Analysts15
Ownership
Shares Out.118.00M
Float108.66M
Insiders6.57%
Institutions106.84%
Short Interest
Short Ratio15.7d
Short % Float16.72%
Short % Out.14.30%
Shares Short16.24M
Short (prev mo.)17.39M
Technical
SMA 5025.23 (-24.3%)
SMA 20022.75 (-16.0%)
Beta2.56
S&P 52W Chg16.45%
Avg Vol (30d)1.31M
Avg Vol (10d)1.51M
Technical Indicators
RSI (14)27.1
MACD-1.5041
MACD Signal-1.0589
MACD Hist.-0.4452
BB Upper27.55 USD
BB Middle23.01 USD
BB Lower18.48 USD
BB Width39.43%
ATR (14)1.201 USD
Vol Ratio (20d)0.81x